A comparative study of deferasirox and deferiprone in the
treatment of iron overload in patients with myelodysplastic
syndromes

J 2013

A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes

CERMAK, Jaroslav; Anna JONASOVA; Jana VONDRAKOVA; Libor ČERVINEK; Petra BELOHLAVKOVA et al.

Základní údaje

Originální název

A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes

Autoři

CERMAK, Jaroslav; Anna JONASOVA; Jana VONDRAKOVA; Libor ČERVINEK; Petra BELOHLAVKOVA a Radana NEUWIRTOVA

Vydání

Leukemia Research, OXFORD, PERGAMON-ELSEVIER SCIENCE LTD, 2013, 0145-2126

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.692

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/13:00071203

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1016/j.leukres.2013.07.021

UT WoS

000327539700004

Klíčová slova anglicky

Deferiprone; Deferasirox;Chelation; Myelodysplasia; Toxicity; Side effects

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 1. 2014 11:36, Soňa Böhmová

Anotace

V originále

One hundred thirteen patients with myelodysplastic syndromes (MDS) with <10% of bone marrow blasts received either deferiprone in a daily dose of 40-90 mg/kg (48 patients) or deferasirox in a daily dose of 10-40 mg/kg (65 patients). Median duration of treatment was 10,9 months for deferiprone and 13,7 months for deferasirox. A substantial reduction of iron stores evaluated as a decrease in serum ferritin of more than 50% of pretreatment level was achieved in 18 patients in deferasirox group (27.7%) but not in any patient treated with deferiprone, The incidence of adverse effects (mostly gastrointestinal symptoms) was similar after administration of both the drugs. The symptoms of deferasirox toxicity were mild and mostly transient and no drug related myelosuppresive effect was observed in contrast to deferiprone where agranulocytosis occurred in 4% of patients and the treatment had to be discontinued due to side effects in 20% of patients. The results confirmed the usefulness of deferasirox as an effective and safe iron chelator in MDS patients and indication of deferiprone as an alternative treatment only in patients with mild or moderate iron overload clearly not indicated for deferasirox.

Citovat

CERMAK, Jaroslav; Anna JONASOVA; Jana VONDRAKOVA; Libor ČERVINEK; Petra BELOHLAVKOVA a Radana NEUWIRTOVA. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. Leukemia Research. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2013, roč. 37, č. 12, s. 1612-1615. ISSN 0145-2126. Dostupné z: https://doi.org/10.1016/j.leukres.2013.07.021.

@article{1160194,
   author = {Cermak, Jaroslav and Jonasova, Anna and Vondrakova, Jana and Červinek, Libor and Belohlavkova, Petra and Neuwirtova, Radana},
   article_location = {OXFORD},
   article_number = {12},
   doi = {https://doi.org/10.1016/j.leukres.2013.07.021},
   keywords = {Deferiprone; Deferasirox;Chelation; Myelodysplasia; Toxicity; Side effects},
   language = {eng},
   issn = {0145-2126},
   journal = {Leukemia Research},
   title = {A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes},
   volume = {37},
   year = {2013}
}

TY  - JOUR
ID  - 1160194
AU  - Cermak, Jaroslav - Jonasova, Anna - Vondrakova, Jana - Červinek, Libor - Belohlavkova, Petra - Neuwirtova, Radana
PY  - 2013
TI  - A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes
JF  - Leukemia Research
VL  - 37
IS  - 12
SP  - 1612-1615
EP  - 1612-1615
PB  - PERGAMON-ELSEVIER SCIENCE LTD
SN  - 01452126
KW  - Deferiprone
KW  - Deferasirox;Chelation
KW  - Myelodysplasia
KW  - Toxicity
KW  - Side effects
N2  - One hundred thirteen patients with myelodysplastic syndromes (MDS) with <10% of bone marrow blasts received either deferiprone in a daily dose of 40-90 mg/kg (48 patients) or deferasirox in a daily dose of 10-40 mg/kg (65 patients). Median duration of treatment was 10,9 months for deferiprone and 13,7 months for deferasirox. A substantial reduction of iron stores evaluated as a decrease in serum ferritin of more than 50% of pretreatment level was achieved in 18 patients in deferasirox group (27.7%) but not in any patient treated with deferiprone, The incidence of adverse effects (mostly gastrointestinal symptoms) was similar after administration of both the drugs. The symptoms of deferasirox toxicity were mild and mostly transient and no drug related myelosuppresive effect was observed in contrast to deferiprone where agranulocytosis occurred in 4% of patients and the treatment had to be discontinued due to side effects in 20% of patients. The results confirmed the usefulness of deferasirox as an effective and safe iron chelator in MDS patients and indication of deferiprone as an alternative treatment only in patients with mild or moderate iron overload clearly not indicated for deferasirox.
ER  -

CERMAK, Jaroslav; Anna JONASOVA; Jana VONDRAKOVA; Libor ČERVINEK; Petra BELOHLAVKOVA a Radana NEUWIRTOVA. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. \textit{Leukemia Research}. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2013, roč.~37, č.~12, s.~1612-1615. ISSN~0145-2126. Dostupné z: https://doi.org/10.1016/j.leukres.2013.07.021.

Přehled o publikaci